X4 Pharmaceuticals Inc
NASDAQ:XFOR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
XFOR's latest stock split occurred on Apr 28, 2025
The company executed a 1-for-30 stock split, meaning that for every 30 shares held, investors received 1 new share.
Before the split, XFOR traded at 0.19 per share. Afterward, the share price was about 5.335.
The adjusted shares began trading on Apr 28, 2025. This was XFOR's 2nd stock split, following the previous one in Mar 14, 2019.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 17, 2026
|
M
|
Miwon Chemicals Co Ltd
KRX:134380
|
10-for-1
x10
|
147900 14790 KRW | 13550 13550 KRW |
|
Apr 17, 2026
|
S
|
Shenzhen Best of Best Holdings Co Ltd
SZSE:001298
|
1-for-1
x1
|
30.47 20.9438 CNY | 21.98 21.98 CNY |
|
Apr 17, 2026
|
T
|
Thanh Thanh Cong - Bien Hoa JSC
VN:SBT
|
53-for-50
x1.06
|
21899.9941 20660.3718 VND | 20650 20650 VND |
|
Apr 17, 2026
|
P
|
Pt Harta Djaya Karya Tbk
IDX:MEJA
|
7-for-6
x1.1666666666667
|
118.0001 101.1429 IDR | 111 111 IDR |
|
Apr 17, 2026
|
|
Yesco Holdings Co Ltd
KRX:015360
|
5-for-1
x5
|
80000 16000 KRW | 16110 16110 KRW |
015360
X4 Pharmaceuticals Inc
Glance View
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company is headquartered in Boston, Massachusetts and currently employs 83 full-time employees. The company went IPO on 2017-11-16. The firm is focused on the research, development and commercialization of therapeutics for the treatment of rare diseases with an initial focus on the treatment of people with immune system dysfunction. Its lead product candidate, mavorixafor, is a small molecule inhibitor of the chemokine receptor CXCR4 and is being developed as a once-daily oral therapy. Its mavorixafor demonstrated ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells (WBCs), which provides therapeutic benefit across a variety of diseases, including primary immunodeficiencies (PIDs) and certain types of cancer. Its mavorixafor is in a global Phase III clinical trial for the treatment of warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome, a rare, inherited PID caused by genetic mutations in the CXCR4 receptor gene. Its product candidates include X4P-001, X4P-002 and X4P-003.
